244 related articles for article (PubMed ID: 15584862)
21. Mammalian target of rapamycin (mTOR) Inhibitors.
Dutcher JP
Curr Oncol Rep; 2004 Mar; 6(2):111-5. PubMed ID: 14751088
[TBL] [Abstract][Full Text] [Related]
22. [mTOR inhibitors: pleiotropic antiproliferative drugs].
Pallet N; Beaune P; Thervet E; Legendre C; Anglicheau D
Med Sci (Paris); 2006 Nov; 22(11):947-52. PubMed ID: 17101096
[TBL] [Abstract][Full Text] [Related]
23. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
24. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
25. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
26. The role of proliferation signal inhibitors in post-transplant malignancies.
Gutiérrez-Dalmau A; Campistol JM
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768
[TBL] [Abstract][Full Text] [Related]
27. The mTOR signaling network: insights from its role during embryonic development.
Hwang M; Perez CA; Moretti L; Lu B
Curr Med Chem; 2008; 15(12):1192-208. PubMed ID: 18473813
[TBL] [Abstract][Full Text] [Related]
28. Targeting the mTOR pathway using deforolimus in cancer therapy.
Mahalingam D; Sankhala K; Mita A; Giles FJ; Mita MM
Future Oncol; 2009 Apr; 5(3):291-303. PubMed ID: 19374536
[TBL] [Abstract][Full Text] [Related]
29. Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Marshall G; Howard Z; Dry J; Fenton S; Heathcote D; Gray N; Keen H; Logie A; Holt S; Smith P; Guichard SM
Biochem Soc Trans; 2011 Apr; 39(2):456-9. PubMed ID: 21428919
[TBL] [Abstract][Full Text] [Related]
30. Mammalian target of rapamycin.
Meric-Bernstam F; Mills GB
Semin Oncol; 2004 Dec; 31(6 Suppl 16):10-7; discussion 33. PubMed ID: 15799239
[TBL] [Abstract][Full Text] [Related]
31. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
Zhang YJ; Duan Y; Zheng XF
Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
[TBL] [Abstract][Full Text] [Related]
32. NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
[TBL] [Abstract][Full Text] [Related]
33. Targeting the mTOR signaling network for cancer therapy.
Meric-Bernstam F; Gonzalez-Angulo AM
J Clin Oncol; 2009 May; 27(13):2278-87. PubMed ID: 19332717
[TBL] [Abstract][Full Text] [Related]
34. Transplantation: time to rethink immunosuppression by mTOR inhibitors?
Säemann MD; Remuzzi G
Nat Rev Nephrol; 2009 Nov; 5(11):611-2. PubMed ID: 19855420
[TBL] [Abstract][Full Text] [Related]
35. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
37. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
[TBL] [Abstract][Full Text] [Related]
38. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
39. Targeting the mTOR pathway in tumor malignancy.
Cheng H; Walls M; Baxi SM; Yin MJ
Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.
Humar R; Kiefer FN; Berns H; Resink TJ; Battegay EJ
FASEB J; 2002 Jun; 16(8):771-80. PubMed ID: 12039858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
